Cardinal Health sets 13-15% EPS growth target on specialty pharma momentum while facing a wage-reimbursement lawsuit
Executive summary: Cardinal Health announced a 13-15% EPS growth target driven by specialty pharmaceutical momentum. Simultaneously, a lawsuit was filed against its subsidiary Cardinal Health 414, LLC alleging failure to reimburse employee business expenses. The EPS target signals confidence in the high-margin specialty distribution business, but the litigation introduces potential legal costs, settlement expenses, and reputational risk that could compress margins.
Who is involved: Cardinal Health (CAH), Cardinal Health 414 LLC, Blumenthal Nordrehaug Bhowmik De Blouw LLP (plaintiffs' counsel), specialty pharma manufacturers, healthcare distributors.
Likely next: Investors will watch the next quarterly earnings call for detail on specialty growth trajectory and any legal reserve disclosures. The lawsuit will proceed to initial pleadings and potential class certification.
Cardinal Health has guided for 13-15% earnings-per-share growth, citing strengthening specialty pharmaceutical distribution. The same day, a class-action lawsuit was filed alleging the company failed to reimburse employees for business expenses, creating a legal overhang that could offset some of the projected earnings gains.
What's next — scenarios
Base: Specialty growth offsets legal costs (55%)
EPS grows 12-14% as specialty volume rises; lawsuit settles for immaterial amount (<$50M) with no change to guidance.
- Q3 2026 earnings beat on specialty revenue
- Lawsuit moves to mediation with low settlement range disclosed
Upside: Specialty acceleration, lawsuit dismissed (20%)
EPS growth exceeds 15% as specialty attach rates improve; legal challenge fails on summary judgment.
- Specialty revenue growth >20% YoY in next two quarters
- Court denies class certification motion
Downside: Legal drag and specialty slowdown (25%)
EPS growth falls to 8-10% as legal reserves build and specialty manufacturer consolidation pressures pricing.
- Specialty gross margin compression >100 bps
- Class certified with potential damages >$200M
What to watch
- Cardinal Health Q3 FY2026 earnings release (expected early November 2026)
- Lawsuit case management conference date (to be set by court)
- Specialty pharmaceutical market growth data from IQVIA (quarterly)
- Any FDA or DEA regulatory actions affecting specialty distribution
Timeline
- — Cardinal Health Targets 13%-15% EPS Growth as Specialty Momentum Builds (Yahoo Finance)
- — Do You Believe Arthur J. Gallagher (AJG) Could Deliver Mid-Teens EPS Growth for Years? (Yahoo Finance)
Analysis — what this means
Likely next events
- Q3 FY2026 earnings call (early Nov 2026) – management commentary on specialty growth and legal reserves
- Initial court scheduling order for Cardinal Health 414 LLC lawsuit (within 60 days)
- IQVIA specialty pharma market report Q3 2026 (late Oct 2026)
Sectors affected
- Healthcare distribution
- Specialty pharmaceutical logistics
- Medical-surgical product distribution
Regulatory implications
- California Labor Code §2802 reimbursement requirements may drive similar claims in other states
- Potential DOL scrutiny of wage-statement accuracy across healthcare distributors
- No specific federal rulemaking cited in sources
Historical parallels
- Arthur J. Gallagher (AJG) targeted mid-teens EPS growth in Sept 2026 as insurance brokerage consolidated – achieved through M&A and organic growth
- McKesson specialty unit (2015-2018) delivered 14% CAGR EPS before opioid litigation created overhang
Key entities
Sources
- Cardinal Health Targets 13%-15% EPS Growth as Specialty Momentum Builds — Yahoo Finance
- Do You Believe Arthur J. Gallagher (AJG) Could Deliver Mid-Teens EPS Growth for Years? — Yahoo Finance
Related cases
- Brady Corp (BRC) faces questions over whether low-margin IPS acquisitions can drive EPS growth
- EPS Connect secures SOC 2 Type II attestation to bolster enterprise security standards
- Block (XYZ) posted a 65% EPS jump yet the share price fell, signaling investor concern over guidance or margin quality
- MKS posted an 86% jump in EPS but warned that margins are under pressure, highlighting a split between earnings strength and profitability concerns
- Company reports Q2 2026 double-digit sales growth and strong EPS growth, raising full-year 2026 guidance
- Ottawa Bancorp posts $1.0 million Q2 profit, EPS $0.42